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Cervical cancera b s t r a c t
Extracellular ATP is known to permeabilize certain cell types to polyatomic cations like YO-PRO1.
Here, we report that extracellularly applied ATP stimulated rapid uptake and accumulation of an
otherwise weakly membrane permeable ﬂuorescent DNA-binding cytotoxin, Hoechst 33258, into
cervical cancer cells. While ATP stimulated Hoechst 33258 uptake in 20–70% of cells from seven cer-
vical cancer cell lines, it stimulated uptake in less than 8% of cervical epithelial cells obtained from
the normal transformation zone and ectocervix tissue of 11 patients. ATP-evoked Hoechst 33258
uptake was independent of ionotropic P2X receptors, but dependent on activation of P2Y receptors.
Thus, we show here that cervical cancer cells can be selectively induced to take up and accumulate
an ionic cytotoxin by exposure to extracellular ATP.
 2015 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
An overriding objective of cancer research is to develop selec-
tive agents for the targeted killing of cancer cells while minimizing
collateral damage to surrounding healthy tissue. To this end, the
majority of current and in-development anti-cancer drugs aretargeted to interfere with critical intracellular components, partic-
ularly those involved in cell survival, and proliferation. Examples
include drugs that interact directly with DNA (cisplatin derivatives,
anthracyclins, and DNA-alkylating agents); drugs that interact
with receptors that affect gene regulation (Tamoxifen, Erlotinib);
and drugs that interfere with cellular metabolism (5-ﬂuorauracil,
methotrexate) [1–3]. The caveat of course is that these drugs must
ﬁrst overcome the barrier imposed by the plasma membrane in
order to reach these intracellular targets. Several commonly used
drugs, including the cisplatin derivatives and the anthracycline,
doxorubicin, exhibit relatively poor passive membrane permeabil-
ity. As a result, a considerable effort has been devoted towards
investigating strategies to enhance cell penetration, including the
use of nanomaterials to encapsulate drugs and facilitate their entry
via passive diffusion or pinocytosis [4], and the use of electrical
membrane disruption [5,6].
An alternative, and potentially less invasive, approach is to uti-
lize a cell’s natural transmembrane transport mechanisms to move
anticancer drugs to the cell interior. It has long been known that
exogenous drugs can serve as substrates for a plethora of facilita-
tive and active transport pumps arrayed on cell membranes.
Many of these pumps, such as those of the large multidrug resis-
tance protein family [7], are primarily responsible for the extrusion
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cancer drugs. However, in the case of cisplatin and its derivatives
a family of copper transporters are as important for the uptake
and accumulation of the drugs in cells as well as their efﬂux [8].
The problem with exploiting these active transport pathways to
enhance anticancer drug penetration, though, is that they often
have a wide tissue distribution and do not have activity easily reg-
ulated pharmacologically.
The experiments described in this paper were conducted based
on the long known ability for extracellular adenosine
50-triphosphate (ATP) to permeabilize certain cell types, such as
mast cells and macrophages, to relatively large polyatomic ions
including 2-amino-2-hydroxymethyl-propane-1,3-diol (TRIS),
N-methyl-D-glucamine (NMDG+) [9], ethidium [10,11], the
Ca2+-sensor Fura-2 and Lucifer Yellow [12,13]. A previous study
had some success with using ATP-evoked permeabilization in
order to load macrophages with doxorubicin and use them as a
release vehicle for the drug in tumors [14]. The mechanism of
ATP-evoked permeabilization is now thought to typically involve
ATP binding and activation of the ion channel, P2X7, which subse-
quently conducts entry of the large cations through its gated trans-
membrane pore [15,16]. However, in some cases, ATP has been
reported to permeabilize cells independently of P2X7 activation
[17–20].
We hypothesized that cervical cancer cells might also be
induced to take up and accumulate cytotoxins through an
ATP-dependent mechanism, and that it might be feasible to thus
induce the permeability of some cancer cells to intracellularly
active cytotoxins. To test this hypothesis, we treated cervical can-
cer cells with one of two DNA-binding cytotoxins, Hoechst 33258
and doxorubicin hydrochloride. Both of these cytotoxins ﬂuoresce
upon binding DNA and subsequently stain the cell’s nucleus, allow-
ing their uptake and accumulation to be monitored using basic ﬂu-
orescence imaging. Hoechst 33258, also known as pibenzimol, is a
cationic, weakly permeable DNA-binding dye known to be cyto-
toxic [21–24], but that was shown to perform poorly against
advanced stage pancreatic cancer in Phase I and II clinical trials
[25,26]. Doxorubicin is a larger anthracycline topoisomerase inhi-
bitor, the electrostatically neutral but water-soluble hydrochloride
salt of which is commonly used in the treatment of cancer. Poor
and subsequently slow transport of anticancer agents across bio-
logical membranes is problematic because it allows for cancer cells
to overcome toxin inﬂux via active efﬂux pathways that utilize
multidrug resistance transporters such as P-glycoprotein [27]. As
we show in this paper, ATP stimulated the rapid uptake and accu-
mulation of one of these toxins, Hoechst 33258, via a mechanism
involving activation of purinergic P2Y receptors. This mechanism
seems to be preferentially active in cancerous cells, being much
less prevalent in cells obtained from normal cervical tissue. Thus,
not only do we demonstrate the feasibility of pharmacologically
enhancing plasma membrane permeability to a cationic cytotoxin,
we also show evidence that this strategy might be utilized to pref-
erentially deliver the drug into cancer cells rather than normal
cells.
2. Materials and methods
2.1. Cervical cell culture
CXT cervical cancer cell lines and normal human cervical
epithelial cells were isolated and cultured from tissue purchased
from the Cooperative Human Tissue Network as described else-
where [28]. Normal and CXT cancerous cells were cultured in
Keratinocyte Serum-Free Medium (KSFM) supplemented with
50 units/mL penicillin G, and 50 lg/mL streptomycin. Normal cellswere used at passages 1–2. HeLa and CaSki cells were cultured in
DMEM supplemented with 10% fetal bovine serum, 2 mM
L-glutamine, 50 units/mL penicillin G, and 50 lg/mL streptomycin.
All cells were incubated at 37 C in a humidiﬁed atmosphere of 5%
CO2.
2.2. Fluorescence imaging
Cells were seeded onto 13 mm borosilicate glass coverslips in
4-well plates at low density. For experiments, the coverslip was
transferred to a perfusion bath on the stage of a Nikon TE200 epi-
ﬂuorescence microscope. The extracellular solution bathing the
cells was of the following composition: 140 mM NaCl, 2.5 mM
KCl, 10 mM HEPES, 10 mM glucose, 0.1 mM CaCl2 (except when
speciﬁed otherwise), and pH adjusted to 7.4 with NaOH). Drugs
were added in ﬁnal concentration via peristaltic pump-mediated
perfusion. Images were acquired and analyzed using lManager
(Professor R. Vale laboratory, University of California, San
Francisco, CA).
2.2.1. Dye uptake experiments
Fluorescence was recorded using appropriate excitation and
emission ﬁlters as follows: Hoechst 33258, 350ex/450em; doxoru-
bicin HCl, 488ex/600em. Images were acquired at 0.1 Hz, 200 ms
exposure. Dye ﬂuorescence over time was recorded as the mean
from all cells in the ﬁeld of view.
2.2.2. Ca2+ imaging
Cells were loaded with the Ca2+ indicator Fluo-4/AM for 30 min
at 22 C, washed thoroughly, and then incubated for 15–30 min
at 37 C to allow for deesteriﬁcation and release of cytosolic
Fluo-4. Images were acquired at 0.2 Hz, 200 ms exposure.
2.3. Patch clamp electrophysiology
Cell were added to the microscope bath chamber of an Olympus
IX51 inverted microscope. The extracellular solution was of the fol-
lowing composition (in mM): 140 NaCl, 0.1 CaCl2, 10 glucose, 10
HEPES, pH 7.4 (NaOH). Plasma membrane currents were recorded
in the broken patch voltage-clamp conﬁguration using an
Axopatch 200B ampliﬁer and digitized using a 1440 Digidata
(Molecular Devices, CA). The cell membrane potential was held
at 60 mV in all cases. Recording pipettes were ﬁlled with a stan-
dard intracellular solution of the following composition (in mM):
140 CsCl, 10 EGTA, 10 HEPES, pH 7.3 (CsOH). Data were recorded
using AxoGraphX (Axograph, CA) software and analyzed ofﬂine
using IgorPro (Wavemetrics, Inc., OR). Drugs were applied using
the Perfusion Fast-Step System SF-77 (Warner Instruments).
2.4. Cell viability
Cells were seeded at low density on glass coverslips in 4-well
IVF plates. The coverslips were removed, washed, treated with
drugs in extracellular solution for 20 min, washed three times with
culture media and replaced in the incubator at 37 C. Cell viability
was assessed at 24 h and 48 h after treatment using an Annexin
V-FITC/propidium iodide viability assay (Sigma–Aldrich, St. Louis,
MO), with all cells showing Annexin V and/or propidium iodide
staining deemed non-viable.
2.5. Cell growth
Cell proliferation was assessed by plating cells at low density
onto 35 mm culture dishes. Viable adherent cells were then
counted using microscopy from 5 ﬁelds of view (4 magniﬁcation)
Fig. 1. Extracellular ATP enhanced accumulation of DNA-binding ﬂuorescent cytotoxins into cervical cancer cells. (A) Cervical cancer cells exposed to Hoechst 33258 (30 lM)
alone for 20 min showed no signs of uptake and nuclear staining. In contrast, cells exposed to extracellular ATP (100 lM) in the continued presence of Hoechst 33258 showed
rapid uptake and accumulation of the cytotoxin. Subsequent assay for propidium iodide (PI) exclusion (3 lM; 5 min) showed that cells were still viable. (B) Pooled time
course data showing Hoechst 33258 uptake in the absence of co-applied purinoceptor agonist (Ctrl) and in presence of ATP or its non-hydrolysable analogue, ATPcS. (C) ATP
did not enhance uptake of, doxorubicin HCl applied up to 100 lM in concentration over a 20 min period. Cells staining by exposure to doxorubicin HCl for 2 h at 37 C are
shown as a positive control. (D) Shows the effect of ATP-evoked Hoechst 33258 loading on cell viability over a 48 h period. Untreated control cells are shown in black; cells
treated for 20 min with ATP (100 lM) alone are shown in green; cells treated with ATP and Hoechst 33258 simultaneously for 20 min are represented both by the blue (% total
cells) and red (% Hoechst-positive cells only) lines. (E) ATP (100 lM) still evoked substantial Hoechst 33258 (30 lM) uptake in subcultured cervical cancer cells seeded from
the survivors of a previous 20 min treatment with ATP and Hoechst 33258. Error bars represent S.E.M. of at least 3 experiments.
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counted at t = 0 for the same plate. Viability was assessed, and
clearly apparent, based on adherence and morphology.
2.6. Reagents
ATP, UTP, Hoechst 33258, doxorubicin, pyridoxalphosphate-6-a
zophenyl-20,40-disulfonic acid (PPADS), U73122, ATPcS, and
BAPTA/AM were purchased from Sigma Aldrich (St. Louis, MO).
Histamine, A740003, and MRS2179 were purchased from Tocris
(Bristol, UK).
2.7. Analysis and statistics
Data are presented as the mean ± S.E.M. Signiﬁcant differences
among groups were determined using GraphPad Prism
(GraphPad, San Diego, CA) using Student’s t-test or one-way
ANOVA with Tukey’s post hoc test as appropriate. A calculated P
value 60.05 was considered signiﬁcant.
3. Results
3.1. ATP-evoked Hoechst 33258 uptake and accumulation in cervical
cancer cells
We ﬁrst examined whether extracellularly applied ATP could
increase the plasma membrane penetration of two candidate cyto-
toxins, Hoechst 33258 and the currently in-use anticancer drug,
doxorubicin hydrochloride (HCl). These cytotoxins were chosen
due to their ﬂuorescence properties when bound to nuclear DNA,
which provided a means by which to assay their time-dependent
penetration into the cell. Live cell time-lapse ﬂuorescence imaging
was used tomonitor cytotoxin uptake and accumulation into adher-
ent cells of a cervical cancer cell line (CXT2) in the absence andpresenceof extracellularATP. In control experiments, cellswereﬁrst
exposed to Hoechst 33258 (Fig. 1A and B), or doxorubicin HCl
(Fig. 1C) alone for 25 min. No cumulative increase in uptake was
observed, consistent with these compounds exhibiting poor passive
membrane permeability over this time frame. In parallel experi-
ments, cells were exposed to ATP (100 lM) in the continued pres-
ence of each of the cytotoxins for 20 min. In cells exposed to
Hoechst 33258, application of ATP evoked a rapid uptake and accu-
mulation of the cytotoxin into cells as shown by an increase in
nuclear ﬂuorescence (Fig. 1A and B). This was not due to
ATP-mediated cell death, as cells were still able to exclude the cell
viability dye propidium iodide when applied after the experiment
(3 lM; 5 min). ATPcS also evoked Hoechst 33258 uptake, showing
that the responsewas not dependent on ATP hydrolysis. In the pres-
ence of 30 lMHoechst 33258, ATP stimulated dye uptake in 58 ± 5%
of CXT2 cells. Over the same 20 min time course, ATP did not evoke
uptake and accumulation of up to 100 lMdoxorubicin HCl (Fig. 1C).
To conﬁrm that ATP-stimulated uptake and accumulation of
Hoechst 33258 was cytotoxic, we exposed cells to either Vehicle
control, ATP alone or ATP in the presence of Hoechst 33258 for
20 min under sterile conditions. The cells were washed thoroughly,
replaced in fresh culture medium and incubated for 24 or 48 h at
37 C, 5% CO2 in a humidiﬁed incubator. Cell viability was then
assessed using an Annexin V/propidium iodide assay. ATP-evoked
Hoechst 33256 uptake was observed to signiﬁcant cell death over
a period of 48 h post-treatment. Total cell viability after treatment
with Hoechst 33258 and ATP (i.e. including both cells that took up
the toxin and those that did not) was reduced to 73 ± 9% over 48 h
compared with 96 ± 0.7% for cells exposed to ATP alone. Among the
cells that took up Hoechst 33258 in the presence of ATP, only
27 ± 9% remained viable (Fig. 1E).
We were curious to see if the fraction (40%) of cells that failed
to take up Hoechst 33258 during exposure in the presence of ATP
were permanently resistant to this treatment. CXT2 cells were
Fig. 2. ATP evoked Hoechst 33258 uptake in abnormal versus normal cervical epithelial cells. (A) ATP (100 lM) evoked Hoechst 33258 (30 lM) uptake and accumulation in
cells of several cervical cancer cell lines and one HPV-immortalized cell line (CX16-10). (B) ATP (100 lM) evoked negligible Hoechst 33258 (30 lM) uptake and accumulation
in normal ectocervical and transformation zone epithelial cells from numerous patients (passages 1–2). (C) Pooled data showing the fraction of abnormal and normal cervical
epithelial cells that accumulated nuclear Hoechst 33258 in the presence of ATP. (D) Comparison showing similar 96 h growth curves for normal and cancerous cell lines. Error
bars represent S.E.M. of at least 3 experiments.
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thoroughly, replaced in media and incubated for 48 h. The surviv-
ing cells were then reseeded in plates and allowed to grow for 48 h
before being exposed to a second round of treatment with ATP and
Hoechst 33258. These were incubated once again for a further 48 h
before being reseeded onto coverslips for imaging experiments.
Having now been exposed to two consecutive treatments of ATP
and Hoechst 33258, we predicted that we would have a subculture
with signiﬁcantly reduced sensitivity to ATP-evoked Hoechst
33258 uptake. Surprisingly, however, we observed ATP-evoked
Hoechst 33258 uptake in 62.4 ± 2.5% of these pre-exposed CXT2
cells, which was not signiﬁcantly different from the uptake fraction
in naïve cells (Fig. 1F).
In summary, application of extracellular ATP permeabilized cer-
vical cancer cells to the DNA-binding cytotoxin, Hoechst 33258,
leading to uptake and accumulation of this cytotoxin. A single
short period of ATP-evoked Hoechst 33258 uptake was subse-
quently sufﬁcient to signiﬁcantly impair cell viability.
Furthermore, cells surviving initial exposures to this treatment
subsequently acquired sensitivity, suggesting that enhanced cell
viability could be achieved by repeated exposure to this treatment.
3.2. ATP preferentially stimulated Hoechst 33258 uptake in abnormal
versus normal cervical epithelial cells
We observed varying degrees of ATP-stimulated Hoechst 33258
uptake in 7 different cervical cancer cell lines (Fig. 2A and C). Thefraction of cells responding to ATP with Hoechst 33258 uptake
was greatest for CXT1 cells (71 ± 17%) and least for the commonly
used cervical cancer cell line, CaSki (8.0 ± 2.1%). The fraction of cells
exhibiting ATP-evoked Hoechst 33258 uptake in HeLa cells were
23 ± 13%. We also observed ATP-evoked Hoechst 33258 uptake in
a human papilloma virus (HPV)-immortalized cell line, CX16-10
(26 ± 6%). In contrast, we consistently observed ATP-evoked
Hoechst 33258 uptake in less than 8% of transformation zone
and ectocervical cells obtained from 11 different healthy patients
(Fig. 2B and C). Based on these data it may be that cervical cancer
cells have an enhanced sensitivity to ATP-stimulated Hoechst
33258 uptake relative to healthy cervical epithelial cells. The abil-
ity for cancer rather than normal cells to appreciably take up
Hoechst 33258 in response to ATP was not a function of cell prolif-
eration rate, as CXT2 cells and normal cells exhibited similar
growth curves (Fig. 2D).
3.3. Role of purinergic receptors in mediating ATP-stimulated Hoechst
33258 uptake and accumulation
Stimulated Hoechst 33258 uptake into CXT2 cells was depen-
dent on the concentration of ATP applied (Fig. 3A) and the concen-
tration of Hoechst 33258 present (Fig. 3B). In addition, we
observed that the ATP-evoked Hoechst 33258 uptake was also
affected by extracellular Ca2+ ([Ca2+]o), and within the physiologi-
cal range (Fig. 3C). Previous studies have shown that the human
P2X7 receptor, a non-selective ATP-gated cation channel, can
Fig. 3. Effect of varying ATP, Hoechst 33258 and extracellular Ca2+ on ATP-evoked
Hoechst 33258 uptake. (A) Hoechst 33258 (30 lM) uptake into CXT2 cells was
dependent on the concentration of ATP applied. (B) Amplitude of ATP (100 lM)-
evoked cytotoxic dye uptake varied with Hoechst 33258 concentration. (C) ATP
(100 lM)-evoked Hoechst 33258 (30 lM) uptake was inhibited by increasing
extracellular Ca2+ concentration ([Ca2+]o). Error bars represent S.E.M. of at least 3
experiments.
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current through these channels is inhibited by extracellular diva-
lents [29]. There is biochemical evidence of P2X7 receptor expres-
sion in cervical epithelial cells, although it appears that cervical
cancer cells upregulate a non-functional splice variant [30,31].
Nevertheless, we set out to test the hypothesis that P2X7 receptors
might be responsible for the observed ATP-evoked uptake in cervi-
cal cancer cells. However, in contrast to the broad spectrum
purinergic receptor inhibitor, PPADS, the putative selective P2X7
receptor antagonist, A-740003, had little effect on ATP-evoked
Hoechst 33258 uptake into CXT2 cells (Fig. 4A). We also observed
no ATP-evoked transmembrane currents in CXT2 cells subjected to
whole cell broken patch clamp electrophysiology, suggestive of an
absence of functional P2X receptors in the plasma membrane of
these cells. Interestingly, we observed that activation of the recom-
binant human P2X7 receptor expressed in HEK293 cells to facili-
tate a marked uptake of Hoechst 33258 uptake; an effect
abolished by A-740003 (Fig. 4B).
ATP can also activate G protein-coupled P2Y receptors, of which
the Gq protein/phospholipase C (PLC) pathway-linked P2Y1 and
P2Y2 receptors are reportedly expressed in cervical epithelial cells
[32,33]. The rate of Hoechst 33258 uptake stimulated by a submax-
imal concentration of ATP (300 nM) was signiﬁcantly reduced by a
maximally effective concentration of the selective P2Y1 antagonist
MRS 2179 (3 lM) (Fig. 4C). We also observed a signiﬁcant but slow
rate of Hoechst 33258 uptake upon exposure of cells to UTP, which
activates P2Y2 receptors. These data suggest that the
ATP-stimulated uptake of Hoechst 33258 is chieﬂy mediated
through P2Y1 receptors with perhaps a small contribution from
P2Y2 receptors.
While it was tempting to speculate that the lack of
ATP-stimulated Hoechst 33258 uptake in normal cervical epithelial
cells might be due to reduced expression of P2Y receptors, we
observed no obvious mean difference in the amplitude and proﬁle
of ATP-stimulated elevations in [Ca2+]i as assayed using the Ca2+
indicator, Fluo-4 (Fig. 4E). Thus, further investigation is needed to
identify the mechanism by which P2Y receptor activation stimu-
lates Hoechst 33258 uptake, and to determine why this phe-
nomenon occurs preferentially in abnormal cervical epithelial
cells relative to health cells. Nevertheless, these experiments pro-
vide compelling evidence that activation of endogenous plasma
membrane receptors can stimulate signaling pathways that func-
tionally permeabilize cancer cells to otherwise weakly membrane
permeable cytotoxins. Furthermore, in the case of cervical epithe-
lial cells, this mechanism is disproportionately active in cancerous
cells versus normal cells, conferring an element of speciﬁcity.
4. Discussion
In this paper we report that extracellular ATP can stimulate the
rapid uptake and accumulation of the ionic DNA-binding cytotoxin,
Hoechst 33258 (pibenzimol), into cervical cancer cells. Thus, in the
presence of ATP Hoechst 33258 penetration of the plasma mem-
brane was virtually immediate, which is in stark contrast to the
several hours required for cells to substantially accumulate the
commonly employed anticancer drug, doxorubicin HCl [34]
(Fig. 1C). Notably, uptake of doxorubicin HCl was not stimulated
by ATP over this time course. The reason for this disparity will be
subjected to further investigation, but likely lies in the selectivity
of the transport mechanism, whether an active transporter or ion
channel. Doxorubicin HCl differs from Hoechst 33258 in terms of
its size, geometry and charge, which might impact its ability to uti-
lize the transport pathway responsible for ATP-evoked uptake.
Fig. 4. ATP-stimulated Hoechst 33258 uptake is mediated by activation of P2Y purinergic receptors. (A) ATP-evoked Hoechst 33258 uptake in cancer cells was inhibited by
PPADS but unaffected by the selective P2X7 antagonist, A740003. Voltage clamp current trace obtained at a holding potential of 60 mV showing no measurable ATP-evoked
current in CXT2 cells (inset). (B) BzATP (100 lM) activation of recombinant human P2X7 receptors expressed in HEK293 cells evoked Hoechst 33258 uptake in a manner
blocked completely by the P2X7-selective antagonist A740003. Voltage clamp current trace obtained at a holding potential of 60 mV showing ATP-evoked current in
HEK293 cell transfected with human P2X7 receptor (inset). (C) The P2Y1 receptor antagonist, MRS2179, signiﬁcantly suppressed Hoechst 33258 uptake evoked by a
submaximal concentration of ATP (300 nM). (D) The P2Y2 agonist, UTP (100 lM), evoked a slow rate of Hoechst 33258 uptake. Error bars represent S.E.M. of at least 3
experiments. Asterisks indicates values signiﬁcantly different from Ctrl (P < 0.05). (E) Representative traces showing ATP (100 lM) stimulated sustained elevations in [Ca2+]i
in both Fluo-4-loaded cancerous (upper panel) and normal (lower panel) cervical epithelial cells. Solid black line indicated mean ﬂuorescence from all cells in the visual ﬁeld;
grey lines indicate individual single cell ﬂuorescence values.
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implies that the mechanism by which ATP permeabilizes cervical
cancer cells is different from that responsible for allowing macro-
phages to be loaded with doxorubicin as reported in an earlier
study [14].
Contrary to our initial hypothesis, uptake of Hoechst 33258 was
not primarily due to permeation through the P2X7 receptor, an
ATP-gated ion channel known to be permeable to large cationic
species [29]. This is despite evidence presented in this paper show-
ing that the recombinant hP2X7 can nevertheless conduct Hoechst
33258 entry into transfected HEK293 cells, and so could potentially
perform the role of drug delivery conduit in other cell types. The
reason we do not observe P2X7-mediated uptake in cervical cancer
is consistent with previous reports indicating that this channel is
signiﬁcantly downregulated during carcinogenesis in these cells
[30], and possibly because the concentration of ATP used is rela-
tively low for activation of human P2X7 receptors [35]. Instead,
ATP stimulation of Hoechst 33258 uptake appears to be dependent
on activation of P2Y receptors.
Importantly, the ATP-evoked Hoechst 33258 uptake phe-
nomenon was not merely a quirk of the CXT2 cancer cell line.
We observed ATP-evoked uptake in >20% of cells in 5 of 7 cancer
cell lines and 1 HPV-immortalized cell line. Importantly, cells that
survived an initial treatment, consisting largely of cells that did not
take up Hoechst 33258 at all, nevertheless demonstrated the same
degree of sensitivity when challenged again at a later time. A pos-
sible explanation for this is that the mechanism responsible for
ATP-evoked Hoechst 33258 uptake is expressed by cells in a
time-dependent fashion, such that cells not expressing the trans-
port mechanism during an initial 20 min treatment may neverthe-
less upregulate it later on, perhaps in a cell cycle-dependent
manner, rendering them sensitive to a subsequent treatment.
This is signiﬁcant, because the susceptible fraction of cancer cells
would be predicted to increase simply as a result of repeated expo-
sure to ATP and Hoechst 33248.In contrast to our observations in cancer cells, only 0.5–8% of
normal cervical epithelial cells exhibited ATP-evoked Hoechst
33258 uptake. The possibility exists, then, that ATP might prefer-
entially permeabilize cancerous and HPV-immortalized cells rela-
tive to normal cells, imparting some speciﬁcity to the
susceptibility of cells to the toxic effects of Hoechst 33258.
Determining the mechanism by which ATP evoked the uptake of
Hoechst 33258, and establishing why this mechanism is preferen-
tially expressed in cancer cells versus normal cells is a goal of
future work.
This apparent ability to pharmacologically activate plasma
membrane uptake and accumulation of a drug is reminiscent of a
recent series of studies involving delivery of an anesthetic into
pain- and itch-processing sensory neurons. Here, the investigators
discovered that they could selectively deliver an otherwise mem-
brane impermeable lidocaine derivative into pain and itch process-
ing cells through the activated TRPV1 and TRPA1 channels
respectively [36–39]. It remains to be determined whether an ion
channel activated downstream of P2Y receptors is responsible for
the ﬁnal transport of Hoechst 33258 that we observe in cervical
cancer cells or whether a carrier protein is involved.
To conclude, we have demonstrated the feasibility of pharmaco-
logically permeabilizing cervical cancer cells to an otherwise
weakly membrane permeable cationic cytotoxin. In cervical cells,
the observed P2Y receptor-dependent drug delivery mechanism
appears to be preferentially active in cancerous cells, possibly
due to the upregulation of some or several required components
of the mechanism. This provides a potential selectivity bonus by
which ionic cytotoxins that would not be easily transported into
healthy cells could have their uptake into cancer cells facilitated.
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